Medicare Advantage vs Traditional Medicare and 30-Day Mortality in Patients With AMI—Reply

In Reply As noted by Dr Roehm, Medicare Advantage health plans principally are paid via capitation payments that are adjusted for the health status of the enrolled population. A large body of research suggests that this payment system has created strong incentives for Medicare Advantage health plans to improve their coding of diagnoses in order to increase their payments. The Medicare Payment Advisory Commission (MedPAC) estimated that Medicare Advantage risk scores in 2021 were more than 10% higher than scores for similar beneficiaries in traditional Medicare . To achieve these scores, Medicare Advantage plans rely on more intensive coding of diagnoses by their clinicians as well as chart audits and home visits to obtain additional diagnosis codes.

Leggi
Aprile 2023

Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in ERBB2/HER2-Positive Breast Cancer

This prognostic study (in which a combined correlative analysis of the CALGB 40601 and PAMELA trials was conducted) compares the effectiveness of tumor-infiltrating lymphocytes vs immune-related gene expression signatures in predicting pathologic complete response and event-free survival in patients with early-stage ERBB2/HER2-positive breast cancer.

Leggi
Aprile 2023

Comparative Effectiveness of Anti-TNF in Combination with Low Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: a Pragmatic Randomized Trial

Tumor Necrosis Factor inhibitors (TNFi), including infliximab and adalimumab, are a mainstay of pediatric Crohn’s disease (PCD) therapy; however, non-response and loss of response is common. As combination therapy with methotrexate may improve response, we performed a multi-center, randomized, double-blind, placebo-controlled pragmatic trial to compare TNFi with oral methotrexate to TNFi monotherapy.

Leggi
Marzo 2023